Stock AnalizBristol Myers Squibb Co. BMY
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Bristol Myers Squibb Co. (BMY) is a healthcare company listed in the US with a market value of about $129.7B. In the twelve months to September 30, 2026 it had revenue of $50.0B and net income of $9.2B, a net margin of 18.5%.
Its overall Stock Analiz score is 2.4 out of 5 (weak). The strongest part is shareholder returns (5/5); the weakest is track record (1/5).
Key numbers: a P/E of 14.1, a price to free cash flow of 14.0, 5-year revenue growth of 3% a year, a 5-year average ROIC of 6%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 2% below the current price.
Score: 2.4 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Profit margin improving
- Strong R&D investment or growth above 20%
- ROE above 15%
- Positive free cash flow
- Pays a dividend
Checks not passed
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $50.0B | $48.2B | $48.3B | $45.0B | $46.2B | $46.4B | $42.5B | $26.1B |
| Net income | $9.2B | $7.1B | -$8.9B | $8.0B | $6.3B | $7.0B | -$9.0B | $3.4B |
| Free cash flow | $9.3B | $12.8B | $13.9B | $12.7B | $11.9B | $15.2B | $13.3B | $7.4B |
| EPS (diluted) | $4.51 | $3.46 | $-4.41 | $3.86 | $2.95 | $3.12 | $-3.99 | $2.01 |
| Net margin | 18.5% | 14.6% | -18.5% | 17.8% | 13.7% | 15.1% | -21.2% | 13.2% |
| ROIC | — | 10.8% | -9.8% | 11.4% | 8.9% | 8.6% | -6.1% | 3.5% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 24 analysts is $65.25, 3% above the current price; targets range from $40.00 to $80.00; the consensus rating is “Buy”; expected EPS is $6.44 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Bristol Myers Squibb’s P/E ratio?
About 14.1, based on the last twelve months of diluted earnings per share (forward P/E about 10.0).
Is Bristol Myers Squibb stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 2% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Bristol Myers Squibb pay a dividend?
Yes. The dividend yield is about 4.01%, and it has paid dividends for 7 years in our data.
Is Bristol Myers Squibb a good stock to buy?
We do not give buy or sell advice. Bristol Myers Squibb scores 2.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.